Skip to main content
. 2018 Jul 26;103(12):2016–2025. doi: 10.3324/haematol.2018.193086

Figure 3.

Figure 3.

The effects of miR-150 overexpression and BCR-ABL1 silencing on the expression of genes in oncogenic pathways in leukemic cells. (A) MYB transcript and MYB protein expression in HL-60 cells 48 hours (h) after the miR-150 transfection. The numbers shown at the top indicate the MYB protein expression relative to that in the untreated samples (β-actin normalized). Expression of MYB transcripts (48 h) and c-MYB protein (96 h) in (B) KCL-22 and (C) K562 after miR-150 transfection and/or BCR-ABL1 activity inhibition with 1 mM imatinib. (D) MYB expression in K562 cells 48 h miR-150 transfection and/or the inhibition of BCR-ABL1 expression by siRNA. (E) miR-155 levels in KCL-22 and K562 cells 96 h after 30 nM miR-150 transfection and/or BCR-ABL1 activity inhibition with 1 μM imatinib. (F) PU.1 expression in KCL-22 and K562 cells 96 h after miR-150 transfection and/or BCR-ABL1 activity inhibition with 1 μM imatinib. (G) MYC expression in KCL-22, K562 and HL-60 cells after exposure to 1 μM imatinib. (H) Pri-miR150, pre-miR150 and miR-150 levels in K562 cells upon BCR-ABL1 inhibition. Generally, cells were transfected with 30 nM miR-150 mimic or 50 nM siRNA BCR-ABL1. The expression data represent the expression fold change (FC; −ΔΔCt) in relation to untreated, control (Ctrl) sample normalized to 1. Unpaired two-tailed Student t-test was used to determine P-values.*P<0.05, **P<0.01, and ***P<0.001. Error bars represent standard deviations.